<DOC>
	<DOCNO>NCT02310477</DOCNO>
	<brief_summary>This large cohort study aim estimate overall survival patient treat regorafenib metastatic colorectal cancer ( mCRC ) within frame french compassionate program .</brief_summary>
	<brief_title>Regorafenib Metastatic Colorectal Cancer : Cohort Study Real-life Setting</brief_title>
	<detailed_description>Regorafenib ( REG ) multi-kinase inhibitor survival benefit patient pretreated mCRC , demonstrate phase III CORRECT study . As result , REG make available medical practice use US , Europe . However , prescribe condition real-life set know less stringent selection criterion clinical trial . The REgorafeniB mEtastatic Colorectal cancer : French Compassionate progrAm ( REBECCA ) ambispective cohort study design elucidate safety effectiveness outcomes associate REG use clinical practice mCRC previously treat , consider candidate , available therapy . Patients identified database French ATU ( Temporary Authorization Use ) , approve French Health Authorities provide early access innovative , yet approve medicinal product REG . Baseline patient tumor characteristic , REG dose dose-intensity , REG-related adverse event , pre- post REG treatment , predictor event , effectiveness data ( PFS , OS ) collect patient agree , physician accept collaborate REBECCA cohort .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patient â‰¥ 18 year old With colorectal cancer metastatic histologically proven Have meet criterion define monograph ATU ( Temporary Authorization Use ) validate French Health Authorities request access treatment validate , patient mCRC use clinical practice mCRC previously treat , consider candidate , available therapy . Patients receive least one dose REG Exclusion criterion : Opposed study Patient meet inclusion criterion Patient deprive liberty guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>regorafenib , cohort , metastatic colorectal cancer</keyword>
</DOC>